INmune Bio falls after Alzheimer's drug trial to remain on hold in US

Inmune Bio

19/12/2023 15:00

** Shares of drug developer INmune Bio Inc  INMB.O  fall
~13.3% to $9.99 
    ** Says late on Monday a mid-stage study testing its
experimental Alzheimer's disease drug will remain on full
clinical hold after being notified by the U.S. FDA
    ** Says the agency requested additional information on
long-term stability of the drug
    ** INMB expects to provide the requested information before
the end of 2023  
     ** Says previously identified clinical hold issues have
been successfully addressed in the U.S. 
    ** Hold will not impact progress in completing the study on
schedule, as patient recruitment projections are reliant on
sites outside of the U.S. - company
    ** The trial is open in Australia, Canada, UK, Poland,
France and Spain and is expected to open soon in several
additional EU countries
    **  The trial was first put on clinical hold in May last
year
    ** Including session moves, stock up ~60% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))